Browse Category

NASDAQ:RBNE News 23 October 2025

Robin Energy’s Wild Ride: Crypto Pivot, Stock Surges, and What’s Next for RBNE?

Robin Energy’s Wild Ride: Crypto Pivot, Stock Surges, and What’s Next for RBNE?

Stock Performance: Wild Swings in Recent Days Robin Energy’s stock has been on a rollercoaster in late 2025. Shares closed yesterday (Oct. 22) at $1.27, up 1.6% from the prior day’s $1.25 close stockinvest.us. In that session, RBNE oscillated between $1.21 and $1.29 (a 6.6% intraday swing) stockinvest.us on higher-than-average volume – about 495,000 shares traded, roughly double the previous day’s turnover stockinvest.us. This mild uptick broke a multi-day losing streak; the stock had fallen in 6 of the past 10 sessions, sliding ~3.8% over two weeks stockinvest.us. Despite this week’s stabilization, Robin Energy remains deep in the red for

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop